Get started

52wkhighs

Cup and handle formation on weekly chart Aurionpro Solution has formed cup & handle on its weekly chart to go long Imp points : 1. It has made a new 52 wk high with more than average recent weekly volume. 2. It has now entered into the zone which has acted as demand zone multiple times earlier. 3. Long wick formation. The handle of weekly chart is forming another cup and handle on daily chart too and has given a breakout with higher volume too. Entry - 90.5 Target - 111.5 SL - 79
NSE:AURIONPROLong
by ankitstockmarket7
$COCP Clears the Runway for a $10+ move In the coming daysBOTHELL, WA,, March 06, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage Biotechnology company discovering and developing novel antiviral therapeutics, today announced it has initiated its Coronavirus program. finance.yahoo.com “Following our acquisition of patent rights and know-how from KSURF and our recently completed financing, we are aggressively pursuing the development of novel antiviral compounds for the treatment of Coronavirus infections using our established proprietary drug discovery platform. Given the global threat of COVID1-9, our primary goal is to advance our Coronavirus program into preclinical development. We will seek opportunities for collaborations as we advance our programs,” stated Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal. Cocrystal recently entered into a license agreement with KSURF to further develop certain proprietary broad-spectrum antiviral compounds for humans to treat Norovirus and Coronavirus infections. Cocrystal intends to pursue research and development of theses antiviral compounds, including preclinical and clinical development. This license advances the Company's antiviral programs significantly by providing potent compounds for further development. For additional information about the Company’s development pipeline, please visit www.cocrystalpharma.com. About Cocrystal Pharma, Inc. Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target influenza viruses, hepatitis C viruses, coronaviruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com. COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that it has entered into a license agreement with Kansas State University Research Foundation (“KSURF”) to further develop certain proprietary broad-spectrum antiviral compounds for the treatment of Norovirus and Coronavirus infections. Under the terms of the agreement, Cocrystal has been granted an exclusive, royalty-bearing right and license to certain antiviral compounds for humans covered by KSURF’s patents. Cocrystal intends to pursue research and development of theses antiviral compounds, including preclinical and clinical development. This license advances the Company's antiviral programs significantly by providing potent compounds for further development. “We are incredibly pleased to contract with the Kansas State University Research Foundation as we seek to develop safe and effective antiviral therapies for these viruses. This license agreement opens several development opportunities for us to expand the broad utility of our platform to address significant viruses for which there are unmet medical needs, particularly the COVID-19 coronavirus and norovirus,” commented Dr. Sam Lee, President of Cocrystal. “There is an urgent demand to address the public health threat that the coronavirus continues to present, and we believe that our proprietary drug discovery platform has the capability to do just that. We intend to seek opportunities for collaborations as we advance these programs.” Cocrystal’s technology generates a 3-D structure of inhibitor complexes at near-atomic resolution providing the Company with the ability to identify novel binding sites, which allows for a rapid turnaround of structural information through highly automated X-ray data processing and refinement. By utilizing this technology, Cocrystal is able to develop compounds that specifically target enzymes that are important to viral replication. The Company is currently leveraging its unique structure-based technologies to develop antiviral drugs for hepatitis C, influenza and norovirus.
NASDAQ:COCPLong
by StockGuild
$QALB Now Pink Current Will Become $CSPS Through CUSIP/Name Chg$QALB management has been moving at break neck speed, after having to amend their filings 3 times they are now fully reporting and pink current and have filed and gotten approved a name change to $CSPS which is due to happen by Friday or sooner. The company has secured all handles for its company on all social media and website alternative names to ensure the security of the company once its fully up and running. Management has already secured several contracts worth millions of dollars giving the company an immediate evaluation above $3 Many updates are on the way per the company and my PPS target remains at $10
QLong
by StockGuild